These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38637785)

  • 21. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
    Ruderman SA; Crane HM; Nance RM; Whitney BM; Harding BN; Mayer KH; Moore RD; Eron JJ; Geng E; Mathews WC; Rodriguez B; Willig AL; Burkholder GA; Lindström S; Wood BR; Collier AC; Vannappagari V; Henegar C; Van Wyk J; Curtis L; Saag MS; Kitahata MM; Delaney JAC
    J Acquir Immune Defic Syndr; 2021 Mar; 86(3):339-343. PubMed ID: 33148997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety of a dolutegravir (DTG)-based antiretroviral treatment (ART) regimen for pregnancy and birth outcomes in Ethiopia: evidence from multicenter cohort study.
    Gedefaw A; Tadesse BT; Berhan Y; Makonnen E; Vella S; Aklillu E
    BMC Infect Dis; 2024 Sep; 24(1):901. PubMed ID: 39223552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
    Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
    J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa.
    Manne-Goehler J; Fabian J; Sokhela S; Akpomiemie G; Rahim N; Lalla-Edward ST; Brennan AT; Siedner MJ; Hill A; Venter WDF
    J Int AIDS Soc; 2024 Jul; 27(7):e26268. PubMed ID: 38978403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of neuropsychiatric adverse events and associated factors among adult patients on dolutegravir attending Mulago ISS clinic.
    Mwebaza J; Meya D; Musiime V; Birungi C
    HIV Med; 2023 Apr; 24(4):491-501. PubMed ID: 36336827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
    Amuge P; Lugemwa A; Wynne B; Mujuru HA; Violari A; Kityo CM; Archary M; Variava E; White E; Turner RM; Shakeshaft C; Ali S; Nathoo KJ; Atwine L; Liberty A; Bbuye D; Kaudha E; Mngqibisa R; Mosala M; Mumbiro V; Nanduudu A; Ankunda R; Maseko L; Kekitiinwa AR; Giaquinto C; Rojo P; Gibb DM; Turkova A; Ford D;
    Lancet HIV; 2022 Sep; 9(9):e638-e648. PubMed ID: 36055295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transition to Dolutegravir Is Associated With an Increase in the Rate of Body Mass Index Change in a Cohort of Virally Suppressed Adolescents.
    Thivalapill N; Simelane T; Mthethwa N; Dlamini S; Lukhele B; Okello V; Kirchner HL; Mandalakas AM; Kay AW
    Clin Infect Dis; 2021 Aug; 73(3):e580-e586. PubMed ID: 33119739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study.
    Zakumumpa H; Kiguba R; Ndagije HB; Ategeka G; Ssanyu JN; Kitutu FE
    BMC Infect Dis; 2022 Aug; 22(1):692. PubMed ID: 35971109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and factors associated with adverse drug events among patients on dolutegravir-based regimen at the Immune Suppression Syndrome Clinic of Mbarara Regional Referral Hospital, Uganda: a mixed design study.
    Namulindwa A; Wasswa JH; Muyindike W; Tamukong R; Oloro J
    AIDS Res Ther; 2022 Apr; 19(1):18. PubMed ID: 35366917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Availability and stock-outs of paediatric antiretroviral treatment formulations at health facilities in Kenya and Uganda.
    Jacobs TG; Okemo D; Ssebagereka A; Mwehonge K; Njuguna EM; Burger DM; Colbers A; Suleman F; Mantel-Teeuwisse AK; Ooms GI
    HIV Med; 2024 Jul; 25(7):805-816. PubMed ID: 38499513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort.
    Chan P; Goh O; Kroon E; Colby D; Sacdalan C; Pinyakorn S; Prueksakaew P; Reiss P; Ananworanich J; Valcour V; Spudich S; Paul R;
    AIDS Res Ther; 2020 Jan; 17(1):1. PubMed ID: 31907064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased Hepatic Steatosis in South African Adolescents With Perinatal HIV Switching to Dolutegravir-containing Regimens.
    Rose PC; De la Rey Nel E; Cotton MF; Otwombe K; Browne SH; Frigati LJ; Rabie H; Innes S
    Pediatr Infect Dis J; 2023 Jul; 42(7):564-572. PubMed ID: 36917035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study).
    Brown JA; Nsakala BL; Mokhele K; Rakuoane I; Muhairwe J; Urda L; Amstutz A; Tschumi N; Klimkait T; Labhardt ND
    HIV Med; 2022 Mar; 23(3):287-293. PubMed ID: 34632682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz.
    Asif S; Baxevanidi E; Hill A; Venter WDF; Fairlie L; Masenya M; Serenata C; Sokhela S; Chandiwana N
    AIDS; 2021 Dec; 35(Suppl 2):S117-S125. PubMed ID: 34261099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings.
    Ndashimye E; Arts EJ
    Int J Infect Dis; 2021 Apr; 105():298-303. PubMed ID: 33722682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
    Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
    PLoS One; 2024; 19(2):e0293162. PubMed ID: 38394297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Excessive Weight Gain Associated With Dolutegravir Initiation in a 10-Year-Old Female With Perinatally Acquired Human Immunodeficiency Virus: A Case Report and Review of the Literature.
    Li J; Yusuf EH; Agwu AL
    J Pediatric Infect Dis Soc; 2021 Apr; 10(3):373-375. PubMed ID: 32448908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The risk of hyperglycemia associated with use of dolutegravir among adults living with HIV in Kampala, Uganda: A case-control study.
    Namara D; Schwartz JI; Tusubira AK; McFarland W; Birungi C; Semitala FC; Muddu M
    Int J STD AIDS; 2022 Dec; 33(14):1158-1164. PubMed ID: 36222490
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and factors associated with hyperglycemia among persons living with HIV/AIDS on dolutegravir-based antiretroviral therapy in Uganda.
    Byereta LH; Olum R; Mutebi EI; Kalyesubula R; Kagimu M; Meya DB; Andia-Biraro I
    Ther Adv Infect Dis; 2024; 11():20499361241272630. PubMed ID: 39286262
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
    PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.